| 000 | 01510 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250513115257.0 | ||
| 264 | 0 | _c19970522 | |
| 008 | 199705s 0 0 eng d | ||
| 022 | _a0887-6924 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchwartsmann, G | |
| 245 | 0 | 0 |
_aDecitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. _h[electronic resource] |
| 260 |
_bLeukemia _cMar 1997 |
||
| 300 |
_aS28-31 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntimetabolites, Antineoplastic _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aAzacitidine _xadministration & dosage |
| 650 | 0 | 4 |
_aBone Marrow _xdrug effects |
| 650 | 0 | 4 |
_aDaunorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aDecitabine |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunophenotyping |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aKaryotyping |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 700 | 1 | _aFernandes, M S | |
| 700 | 1 | _aSchaan, M D | |
| 700 | 1 | _aMoschen, M | |
| 700 | 1 | _aGerhardt, L M | |
| 700 | 1 | _aDi Leone, L | |
| 700 | 1 | _aLoitzembauer, B | |
| 700 | 1 | _aKalakun, L | |
| 773 | 0 |
_tLeukemia _gvol. 11 Suppl 1 _gp. S28-31 |
|
| 999 |
_c9112205 _d9112205 |
||